Here, we describe two cases of severe pyogenic infection in healthy donors diagnosed immediately following stem cell mobilisation with G-CSF. In the first donor a painful perianal abscess and in the second one an apical abscess required surgical incision. The reported serious adverse events in the literature are reviewed and the potential pathophysiological role of G-CSF or GM-CSF in augmenting inflammatory processes is discussed. In the light of a rapidly increasing number of related and unrelated peripheral blood stem cell donations the need for more comprehensive donor work-up and follow-up for peripheral blood stem cell donors has to be considered. Bone Marrow Transplantation (2000) 26, 811-813.
Peripheral blood stem cells (PBSC) are increasingly being used as a source of marrow repopulating cells in allogeneic stem cell transplantation. [1] [2] [3] [4] [5] [6] [7] [8] 
PBSC transplantation with G-CSF mobilised CD34
+ progenitor cells results in significantly faster myeloid and lymphoid recovery as compared with conventional BMT 9 . The advantages for the donors are: (1) no need for general anaesthesia; and (2) no sequelae of the explantation procedure. 8, 10 Administration of G-CSF is generally well tolerated and serious adverse events in healthy donors are rare. bodyweight (BW) given twice daily as s.c. bolus injections for 4 consecutive days. Donor check-up and clearance were performed according to the World Marrow Donor Association (WMDA) guidelines 13 including medical history, physical examination, chest X-ray, ECG, full blood count including differential, biochemistry, and infectious disease markers including C-reactive protein (CRP). On day 5 (the day of the first leukapheresis), a painful apical abscess of tooth 13 was diagnosed requiring surgical incision and broad-spectrum antibiotics. At this time leucocytes were 41.4 × 10 9 /l, CRP 0.88 mg/dl, and body temperature was slightly elevated at 37.8°C. Routine microbiological cultures of the abscess were sterile. In agreement with the donor two large-volume leukaphereses were completed using a Baxter Healthcare CS3000 plus blood cell separator (Baxter, Deerfield, IL, USA), resulting in collection of Ͼ3.0 × 10 6 CD34 + cells/kg recipient BW. Routine cultures of the leukapheresis product were sterile. Now, more than 2 years after stem cell donation, the donor still has no longterm sequelae. The early post-transplant period of the recipient, a 46-year-old male suffering from secondary AML, was complicated by one episode of Enterococcus spp. bacteremia on day +7, which promptly responded to broad-spectrum antibiotics. The patient engrafted on day +18, but died on day +104 due to CMV enteritis.
Case 2
In March 1999, G-CSF was administered to a 42-year-old male, HLA-identical, MLC-negative sibling donor following donor work-up and clearance as described above. On days 5 and 6 two large-volume leukaphereses resulted in collection of Ͻ4.0 × 10 6 CD34 + cells/kg recipient BW. Routine cultures of leukapheresis products were sterile. The following day the patient complained of having a slight twinging pain in the left leg, and 3 days after G-CSF had been discontinued a painful perianal abscess requiring surgical incision was diagnosed. Klebsiella spp., coagulasenegative Staphylococci, Corynebacterium sp., and Streptococcus viridans were isolated by routine culture of the abscess content. Moreover, the donor had to be treated with broad-spectrum antibiotics for 7 days because of fever, leukocytosis (17 × 10 9 /l) and an elevated CRP (16 mg/dl). Symptoms quickly disappeared, and 1. years after stem cell mobilisation the donor is well without any long-term sequelae of the mobilisation procedure. The recipient, a 36 yearold female with metastatic breast cancer, experienced one episode of fever of unknown origin (FUO) on day +1, which was successfully treated with broad-spectrum antibiotics. Leucocyte engraftment was seen on day +13. No other infections were diagnosed in the early post-transplant period, and the patient died 120 days post SCT due to progressive disease.
Discussion
We have described two cases of severe pyogenic infection in healthy donors diagnosed immediately following stem cell mobilisation with G-CSF. In a large retrospective analysis defining safety and efficacy of allogeneic peripheral blood progenitor cell collection moderate to severe side-effects of G-CSF administration including bone pain, headache, fatigue, and nausea were reported to occur in about 50% of the donors. 11 Other reversible side-effects include non-cardiac chest pain, minor local reactions at the injection site, insomnia, dizziness, subfebrile temperatures and changes in laboratory parameters. 10, 11, 14, 15 Serious adverse events, however, are rare but have been noticed in patients, as well as in healthy donors receiving G-CSF for the purpose of stem cell mobilisation. G-CSF has been discussed as the causative agent for the occurrence of Sweet syndrome, leukocytoclastic vasculitis, interstitial pneumonitis, adult respiratory distress syndrome (ARDS), pyoderma gangraenosum, capillary leakage, stroke, acute gouty arthritis, iritis, severe anaphylactoid reactions, and non-traumatic rupture of the spleen. 11, [16] [17] [18] [19] [20] [21] [22] [23] [24] On the other hand, growth factors such as G-CSF and GM-CSF have been proven to reduce the incidence of documented infections in neutropenic patients and they have been shown to reduce the risk of pyogenic infections in patients with chronic granulomatous disease. 25 In contrast, by increasing the activity of the oxidative burst in neutrophils a pathophysiological role of these substances in augmenting inflammatory processes in persons or patients with normal or even subnormal neutrophil counts and/or function must be discussed (for summary see Spiekermann et al 16 ). In animal models such effects of hematopoietic growth factors negatively affected survival after the onset of sepsis due to neutrophil-and cytokine-induced tissue damage. 26 In humans, increased antibody-dependent cellular cytotoxicity (ADCC), increased adherence, phagocytosis, and bacterial killing might be responsible for the association of G-CSF treatment and neutrophilic dermatoses, vasculitides, and bullous pyoderma gangraenosum. 17, 18 Induction of secondary inflammatory cytokines by G-CSF has been discussed as being responsible for the occurrence of ARDS during G-CSF treatment for druginduced neutropenia. 27, 28 However, the capacity of G-CSF to induce secondary cytokines and/or chemokines or chemoattractants that may be instrumental in orchestrating the progression of inflammation remains controversial. 29 Recently, anti-inflammatory properties of G-CSF by downregulation of TNF-␣, IL-12, and IFN-␣ release in response to LPS after a prolonged administration of G-CSF at dosages even lower than used for stem cell mobilisation have been reported. [30] [31] [32] In contrast, short-term administration or single-dose G-CSF was found to increase plasma levels of TNF-␣ in healthy volunteers receiving endotoxin, 33 thereby probably augmenting inflammatory processes.
Nevertheless, the pyogenic infections directly associated with the administration of G-CSF observed in our two healthy donors occurred despite careful donor check-up and clearance according to WMDA guidelines and despite negative infectious disease markers including CRP. It is noteworthy, that both infections remained localised in the donor and did not lead to contamination of the stem cell products or to infection of the immunocompromised host. In light of an increasing number of related and even unrelated peripheral blood stem cell donations in the near future a more comprehensive donor work-up and of course follow-up for peripheral blood stem cell than for conventional bone marrow donors will be necessary.
